> All the big AIM fraud exposés
> 300 articles and podcasts a month
> Hot share tips
> Original investigations by our experienced team
> No ads, no click-bait, no auto-play videos
By Tom Winnifrith | Wednesday 7 February 2018
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
You will have read our detailed coverage of Neil Woodford's woes and especially those of his uber dog listed investment company Woodford Patient Capital Trust (WPCT). Our sell advice has saved our readers thousands of pounds. But we believe in balance and so below is the advice of The Times Tempus column which is to buy. It is poorly researched - compare its coverage of Atom Bank with ours HERE) for instance and reads as if it was dictated by a PR person as is so often the case with the stinking carcass that is the deadwood press. Here goes...
You gotta have faith that Woodford patient capital will produce the hits
If Neil Woodford had thrown darts at a wall covered with the names of potential investments, he would have been unlucky to have ended up buying some of the stinkers that litter his trio of portfolios.
Take the Woodford Patient Capital Trust. The fund’s premise is that those investing in it should take the long view; think at least a decade, not months, not years. Fair enough. Yet serious questions have been raised about some of Mr Woodford’s picks, most prominently of late Prothena, a drug developer that short-sellers claim is a giant turkey. The company’s shares, the trust’s second largest holding, have fallen by more than 40 per cent in the past three months, as the market appears to agree.
Then there is Purplebricks. Analysts at Jefferies, the American investment bank, have claimed for some time that the online estate agent, the trust’s fourth largest holding, is fiddling its numbers to present an artificially rosy impression of its sales figures. Purplebricks had been the largest single contributor to the trust’s performance, but in the past week the stock has lost nearly a fifth of its value.
The problems are not restricted to the trust. The Woodford Equity Income Fund, Mr Woodford’s main vehicle, has watched several of its biggest bets go sour in the past year. Imperial Brands, its largest stake, is down more than 20 per cent. Astrazeneca has recovered from its lows last summer but is hardly a stellar performer. But these are sideshows compared with the collapse at Provident Financial, a top ten holding, that has lost three quarters of its value amid a catastrophic reorganisation at the sub-prime lender.
In fairness to Mr Woodford, who is nothing if not open, his approach has always been one of studied contrarianism. Yet even among the faithful there is a sense that this time may be different as investors have watched him try to defend his decision to increase a holding of Capita only weeks before a profit warning that led the share price to halve last week.
“This isn’t underperformance relative to other styles but a significant misreading of companies’ prospects and their performance,” one apparently long-term follower of Mr Woodford wrote on his investment firm’s website.
Some big money has already abandoned the funds. Jupiter Asset Management withdrew £450 million last year and Aviva has taken out about £30 million of its clients’ cash, but what of those who may not like the performance of an individual fund but believe that the former Invesco Perpetual star manager has not lost his old magic? For these hardy folks, the Patient Capital Trust probably remains the best bet. The fund is UK-focused and as much as 80 per cent unquoted, meaning that it is hard to tell yet whether its bets have come off.
The point is that those who choose to buy into the trust must have plenty of faith in Mr Woodford and his team’s ability to spot the early investments that will offer outsize payoffs. Only one or two mega-hits can make up for a batch of rubbish. If Atom Bank, the online lender, can grab a sliver of the market share of the high street banks, investors could be rewarded handsomely. If Ratesetter can overcome some recent travails, the peer-to-peer lender could be rewarded with a lucrative valuation in a flotation — and that is before you look through the long list of healthcare investments, any one of which could provide the fund’s ultimate payday.
That, of course, is to place a lot of faith in Mr Woodford, but then what were investors doing putting their money there in the first place if they didn’t have that faith?
Why If you want a patient investment, then you’ve got to take the rough with the smooth
Never miss a story.
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Comments are turned off for this article.
Search ShareProphets |
Stock market news |
Recent Comments |
Site by Everywhen